Iovance Biotherapeutics (IOVA) Misses Q1 EPS by 5c ; Offers Guidance

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q1 EPS of ($0.19), $0.05 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $71.43 million versus the consensus estimate of $80.93 million.

GUIDANCE:

Iovance Biotherapeutics sees Q2 2026 revenue of $86-88 million, versus the consensus of $84.36 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• A.O. Smith executive chairman to retire, CEO to assume chairman role
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings